Get the Stockscreener App
0.803
0.90%
-0.0073
After Hours:
.80
-0.003
-0.37%
Clearmind Medicine Inc stock is traded at $0.803, with a volume of 56,661.
It is down -0.90% in the last 24 hours and down -53.04% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$0.8103
Open:
$0.84
24h Volume:
56,661
Relative Volume:
0.08
Market Cap:
$2.70M
Revenue:
-
Net Income/Loss:
$-7.90M
P/E Ratio:
-0.00432
EPS:
-185.9263
Net Cash Flow:
$-6.29M
1W Performance:
+0.45%
1M Performance:
-53.04%
6M Performance:
-88.85%
1Y Performance:
-99.81%
1-Day Range:
$0.8021
$0.84
1-Week Range:
$0.7723
$0.8508
52-Week Range:
$0.77
$480.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.803 | 2.70M | 0 | -7.90M | -6.29M | -185.93 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind Medicine reports three published US patent applications - Mugglehead Investment Magazine
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations - Yahoo Finance
Three patent applications pair LSD, ketamine and ibogaine with a proprietary compound. - Stock Titan
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations - thenewswire.com
NeuroThera Labs Expands U.S. Patent Portfolio With LSD, Ketamine and Ibogaine Combinations via Clearmind Collaboration - kalkine.ca
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations - The Manila Times
Clearmind Medicine Announces U.S. Publication of Patent Applications Covering LSD, Ketamine and Ibogaine Combinations with N-Acylethanolamines - Quiver Quantitative
Clearmind testifies at FDA hearing on psychedelic therapies - Investing.com
Clearmind testifies at FDA hearing on psychedelic therapies By Investing.com - Investing.com Canada
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. - The Manila Times
About 1,800 people joined the FDA’s psychedelic hearing. Clearmind spoke on patient access. - Stock Titan
Why Did CMND Stock Jump 40% Today? - Stocktwits
Clearmind enrolls first AUD patients in CMND-100 trial - grafa.com
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial - The Manila Times
Clearmind enrolls first AUD patients in CMND-100 clinical trial By Investing.com - Investing.com UK
Two patients become the first to receive Clearmind's potential treatment for alcohol use disorder. - Stock Titan
Clearmind enrolls first AUD patients in CMND-100 clinical trial - Investing.com
Proposed Nasdaq threshold could threaten Clearmind (NASDAQ: CMND) listing - Stock Titan
Clearmind Medicine(CMND) Stock Options Chain | Quotes & News - Moomoo
Charging Robotics Inc. Sells Majority Stake in Charging Israel to Clearmind Medicine for $2.5M (OTC: CHEV) - kalkinemedia.com
Clearmind gets Yale IRB approval for AUD trial enrollment By Investing.com - Investing.com India
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results - The Manila Times
All 24 trial participants completed treatment with no serious adverse events. Yale can now recruit. - stocktitan.net
Clearmind to acquire 51% stake in EV charging firm for $2.5M By Investing.com - Investing.com Australia
Clearmind Medicine to Acquire Majority Stake in Charging Robotics for $2.5 Million - marketscreener.com
CMND Stock Slides As Clearmind Medicine Tightens Cash Belt - StocksToTrade
Clearmind Tumbles on Buying into Charging Robotics - Baystreet.ca
Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million - Yahoo Finance
Clearmind Medicine Stock Slides Friday: What's Happening? - Benzinga
CMND Stock Slides As Traders Eye Key Support Levels - timothysykes.com
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis - The Manila Times
Clearmind Medicine CMND-100 Advances As Psychedelic Pipeline Builds - StocksToTrade
Clearmind to acquire 51% stake in EV charging firm for $2.5M - Investing.com UK
Clearmind Medicine Inc. (CMND) moves into EV wireless charging with a controlling deal - Stock Titan
Clearmind Medicine ลงนามในข้อตกลงขั้นสุดท้ายเพื่อเข้าซื้อหุ้น 51% ในบริษัทระบบชาร์จไร้สายสำหรับระบบจอดรถอัตโนมัติและรถแท็กซี่ไร้คนขับ (Robotaxis) - Moomoo
Debt-for-share swap at $1 sets new floor at Clearmind (CMND) - Stock Titan
Clearmind Medicine Inc. (CMND) Stock: Jumps Nearly 10% as Phase IIa AUD Trial Begins - Blockonomi
Clearmind starts Phase IIa AUD trial of CMND-100 - Stock Titan
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled - The Manila Times
Clearmind Medicine Announces Initiation of Phase IIa Trial for CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine (CMND) Slips 2.76% to $1.76, Holds Above Key Support at $1.67ALMA Signal - careplusvn.com
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - The Manila Times
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - NewMediaWire
SciSparc: NeuroThera-Clearmind Collaboration Advances - GlobeNewswire
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionVolume Rate Change - vinanet.vn
Clearmind Medicine Company Profile & Introduction - Moomoo
Clearmind Medicine (CMND) Holds Near $1.86 as Biotech Stock Consolidates Within Key RangeFibonacci Extension - vinanet.vn
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial - Benzinga
Clearmind Medicine Receives DSMB Approval to Advance CMND-100 Clinical Trial in Patients With Alcohol Use Disorder - Quiver Quantitative
Clearmind's CMND-100 Will Be Tested in People With Alcohol Use Disorder - Stock Titan
Clearmind Medicine Inc. (NASDAQ:CMND) - intelligentinvestor.com.au
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):